Refractory circulatory failure in COVID-19 patients treated with veno-arterial ECMO a retrospective single-center experience.
Clemens WiestAlois PhilippMaik FoltanFlorian GeismannRoland SchneckenpointerSimon BaumgartnerFlorian StichtFlorian HitzenbichlerMichael ArztChristoph FisserAndrea StadlbauerThomas DienemannLars Siegfried MaierDirk LunzThomas MuellerMatthias LubnowPublished in: PloS one (2024)
Survival on VA-ECMO in COVID-19 depends on VA-ECMO indication, which should be considered in further studies and clinical decision making. A subgroup of patients suffers from acute heart failure due to inflammation, which has to be differentiated into septic or COVID-19 associated. Novel biomarkers are required to ensure reliable differentiation between these entities; a candidate might be soluble interleukin 2 receptor.
Keyphrases
- extracorporeal membrane oxygenation
- coronavirus disease
- sars cov
- acute respiratory distress syndrome
- acute heart failure
- respiratory failure
- decision making
- end stage renal disease
- ejection fraction
- newly diagnosed
- respiratory syndrome coronavirus
- heart failure
- acute kidney injury
- prognostic factors
- mechanical ventilation
- peritoneal dialysis
- open label